A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70300 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Iona Davies und 11 weiteren Autor:innen. Beteiligte Einrichtung: Section of Endocrinology and Investigative Medicine, Imperial College London, London, UK. Hauptthemen laut MEDLINE: Receptors, Gastrointestinal Hormone, Obesity. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biotechnology and Biological Sciences Research Council, Eli Lilly LRAP programme, MRC Doctoral Training Partnership.
Abstract (Originalsprache)
Aims
Targeting the glucose dependent insulinotropic polypeptide receptor ( GIPR ) is of growing interest for treating type 2 diabetes and obesity, though the optimal approach remains unclear. Both GIPR agonism and antagonism, respectively, incorporated into drugs like tirzepatide and maridebart cafraglutide, have paradoxically both shown significant weight loss effects in humans. Materials and methods In this study, the metabolic impacts of a GIPR agonist (GIP108) and antagonist (NN‐GIPR‐Ant) were evaluated in lean and high‐fat diet (HFD)–induced obese male mice. We assessed the impacts on food intake, body weight, glucose and insulin tolerance, liver triglyceride levels, bone markers and adipose tissue lipolytic gene expression.
Results
In lean mice, neither peptide affected food intake or body weight, but GIP108 improved glucose tolerance. In obese mice, both agents reduced food intake and body weight, with NN‐GIPR‐Ant producing more sustained appetite suppression. Energy expenditure remained unchanged, as weight loss matched that of pair‐fed controls. GIP108 improved glucose tolerance independently of weight loss, whereas NN‐GIPR‐Ant reduced insulin sensitivity compared to pair‐fed controls. Both treatments slightly increased liver triglyceride content compared to their pair‐fed controls, and no treatment significantly affected plasma bone marker levels. Finally, NN‐GIPR‐Ant reduced the expression of adipose tissue lipolytic genes.
Conclusions
Our data highlights the distinct metabolic effects of GIPR agonism and antagonism, offering insights for their future application in personalised metabolic disease treatments. Further human studies are needed to understand the long‐term metabolic impacts of these therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Endocrinology and Investigative Medicine, Imperial College London, London, UK.
ORCID-Profile: Ben Jones, Tricia M M Tan
Förderung
- Biotechnology and Biological Sciences Research Council
- Eli Lilly LRAP programme
- MRC Doctoral Training Partnership
- Wellcome Trust
- Medical Research Council
- Diabetes UK
- NIHR BRC
- Metsera Inc
Zitieren
APA
Davies, I., Turland, A., Tran, H. D., Wong, C., Cahn, O., Dunsterville, C., Sun, Y., Xiao, Y., Murphy, K. G., Bloom, S. R., Jones, B., & Tan, T. M. M. (2026). A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70300
Vancouver
Davies I, Turland A, Tran HD, Wong C, Cahn O, Dunsterville C, et al. A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70300
BibTeX
@article{Davies2026,
author = {Davies, Iona and Turland, Alexandra and Tran, Hanh Duyen and Wong, Carissa and Cahn, Olivier and Dunsterville, Cecilia and Sun, Yichang and Xiao, Yilin and Murphy, Kevin G and Bloom, Stephen R and Jones, Ben and Tan, Tricia M M},
title = {A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70300}
}
EUVIMED